Bristol-Myers Squibb Company and Simcere Pharmaceutical have expanded their pharma deals formed in 2010.
The companies have agreed pharma deals to collaborate in China on the development and commercialization of the subcutaneous formulation of Bristol-Myers Squibb’s biologic medicine, Orencia (abatacept), for the treatment of rheumatoid arthritis.
Orencia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan.
Bristol-Myers Squibb, a big pharma company, and Simcere Pharmaceutical announced pharma deals to co-develop BMS-817378, a preclinical small molecule MET/VEGFR-2 inhibitor in 2010.
The previous pharma deals stated that Simcere receives exclusive rights to develop and commercialize BMS-817378 in China while Bristol-Myers Squibb retains exclusive rights in all other markets.
Report: Partnering Deals and Alliances with Bristol-Myers Squibb
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity